The 340B Drug Pricing Program (340B program) is a federal drug discount program that requires drug manufacturers participating in the Medicaid drug rebate program to provide outpatient drugs to ...

Amid ongoing controversy over 340B drug discounts, a sweeping review suggests the program is doing what it was intended to do: generate revenue for hospitals, clinics and pharmacies by requiring ...

Changes to registration requirements for the offsite clinics of 340B-eligible hospitals represent the latest clash between providers, regulators and drugmakers amid the program’s exponential growth.

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. The Trump administration will pilot a voluntary ...

One of the world’s biggest drug makers is suing the country’s smallest state. The argument is over a federal drug discount program ...

Americans assume hospitals are in the business of keeping us healthy, not of buying drugs inexpensively and then reselling ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its toes into the 340B debate, hospital groups express concerns about the potential for cash flow ...